FDA Approves Drug to Treat Agitation in Alzheimer’s Dementia
Reading Time: < 1 minute
Agitation seen in dementia is among many of the common causes that lead to caregiver burnout and community/facility placement and can lead to resident quality of life issues. On Thursday, May 11th, the Food and Drug Administration approved, for the first time, a drug to treat agitation symptoms in Alzheimer’s disease. The drug, Rexulti, is an antipsychotic medication whose new approval covers its use as a once-daily treatment to ease emotional symptoms over time. This is the first FDA-approved treatment option for this indication.
Memory Care Simpsonville SC – FDA Approves Drug to Treat Agitation in Alzheimer’s Dementia
Check out these articles from Alzheimer’s News Today, McKnights Long-Term Care News, and the FDA News Release for more information.
